

## Our Commitment

In order to assist you to meet the requirements of your accreditation contract with the United Kingdom Accreditation Service (UKAS), we proactively declare the status of our quality to laboratories that send work to us and we seek to assure you of our continuing commitment to quality and to the needs of our patients, donors and laboratory users.

## Network Details & Status

H&I is a UKAS accredited Medical Laboratory **No.9239**.

Our laboratories maintain UKAS accreditation in all areas with accreditation assessment under ISO15189. The scope of our accreditation is listed at [www.UKAS.com](http://www.UKAS.com)

Each of our laboratories is directed by a Consultant Clinical Scientist who undertakes appropriate CPD.

## General Information

Lab	Head of Lab	Address
H&I Barnsley	Tim Key	NHS Blood and Transplant, Barnsley Blood Centre (Unit D), Capital Way, Dodworth, Barnsley, S75 3FG
H&I Birmingham	Luke Foster	NHS Blood and Transplant, Vincent Drive, Edgbaston, Birmingham, B15 2SG
H&I Colindale	Dr. Colin Brown	NHS Blood and Transplant, Charcot Road, Colindale, London, NW9 5BG
H&I Filton	Dr. Anthony Poles	NHS Blood and Transplant, 500, North Bristol Park, Bristol, BS34 7QH
Molecular Diagnostics		NHS Blood and Transplant, 500, North Bristol Park, Bristol, BS34 7QH
H&I Newcastle	Dr. Arash Akbarzad-Yousefi	NHS Blood and Transplant, Holland Drive, Barrack Road, Newcastle-upon-Tyne, NE2 4NQ
H&I Tooting	Dr. Deborah Sage	NHS Blood and Transplant, 75 Cranmer Terrace, Tooting, London, SW17 0RB
Websites	<a href="https://hospital.blood.co.uk/">https://hospital.blood.co.uk/</a> (H&I) <a href="https://ibgri.blood.co.uk/">https://ibgri.blood.co.uk/</a> (Molecular Diagnostics)	

## Statement of Commitment

For our network to comply with the requirements of the standards above, we recognise that external laboratories referring work are required to periodically review their arrangements with us and seek assurances that we continue to comply with their expectations of all the services that we provide. This applies to all work referred and spans all tests and clinical/interpretive services. Provided that the samples sent, and the accompanying requests have complete supporting information, we will ensure that we are committed to the following:

1. We will inform you as quickly as possible of any tests that we undertake for you where we believe that the results provided, are for any reason, unreliable.
2. We will inform you as soon as possible of any circumstances that adversely affect our turnaround times or the quality of services that we provide to you.
3. We are registered with an appropriate EQA scheme for the services we provide to you and that we will inform you of any adverse EQA that results in persistent poor performance and/or where we have been referred to the advisory panel.
4. We will inform you of any changes to sample requirements for the tests that we perform for you.
5. We will inform you of any changes that could lead to results or their interpretation being significantly different for the tests we perform for you.

## Patient / Donor / Laboratory User Information

### Laboratory user guides

Information on the tests performed at each laboratory including the test turnaround times and sample requirements are all listed in our user guides which are available at:

*H&I laboratories:*

INF136 - <https://hospital.blood.co.uk/diagnostic-services/histocompatibility-and-immunogenetics/>

*Molecular Diagnostics laboratory:*

Fetal RHD screening test - <https://ibgri.blood.co.uk/services/molecular-diagnostics/fetal-rhd-screen/>

Fetal genotyping diagnostic - <https://ibgri.blood.co.uk/services/molecular-diagnostics/fetal-genotyping-diagnostic/>

## Patient leaflets

### H&I:

Solid organ and Haematopoietic stem cell transplantation, H&I services related to transfusion, Immunogenetics – HLA and disease association, Platelet and Granulocyte immunology - <https://hospital.blood.co.uk/diagnostic-services/histocompatibility-and-immunogenetics/patient-information-leaflets/>

### Molecular Diagnostics:

Blood Groups and Red Cell Antibodies in Pregnancy - <https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/18055/inf166-blood-groups-and-red-cell-antibodies-in-pregnancy.pdf>

D negative mother's blood test to check her unborn baby's blood group - <https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/26649/inf126332-d-negative-mothers-blood-test-to-check-her-unborn-babys-blood-group.pdf>

## Test request forms

### H&I

3A to 3F : <https://hospital.blood.co.uk/diagnostic-services/histocompatibility-and-immunogenetics/hi-test-request-forms/>

### Molecular Diagnostics:

Blood Group Genotyping: <https://ibgri.blood.co.uk/services/molecular-diagnostics/red-cell-genotyping/>

Fetal Genotyping from Maternal Blood - <https://ibgri.blood.co.uk/services/molecular-diagnostics/fetal-genotyping-diagnostic/>

Fetal RHD screening - [Fetal RHD screen - International Blood Group Reference Laboratory - NHS Blood and Transplant](#)

## Participation in External Quality Assessment (EQA)

Molecular Diagnostics	UK NEQAS Haematology & Transfusion	Red Cell Genotyping
	DEKS - Danish Institute for External Quality Assurance	Non-invasive fetal RhD genotyping
	College of American Pathologists	HEA Beadchip Red Blood Cell Antigen Genotyping
H&I	UK NEQAS H&I	Scheme 1b - HLA-B*27 testing
		Scheme 2a - cytotoxic crossmatching
		Scheme 3 - HLA antibody specificity analysis
		Scheme 4a1 – DNA HLA typing at 1st field resolution
		Scheme 4a2 – DNA HLA typing at 2nd or 3rd field resolution
		Scheme 5a - HFE typing
		Scheme 6 – HLA antibody detection
		Scheme 10 – HPA genotyping
		Scheme 11 – HPA antibody detection specification
	UK NEQAS Leucocyte Immunophenotyping	Post SCT chimerism monitoring
	Referenzinstitut für Bioanalytik (RfB)	CCR5 Detection
	ECAT Foundation	HIT -I (immunological testing)
	INSTAND e.V	233 Immunohaematology 03 - Platelet Immunology
	INSTAND e.V	234 Immunohaematology 04 - Granulocyte Immunology

Any episodes of poor performance are managed through the quality management system. H&I does not release details of specific EQA results. Notifications of unsatisfactory performance from the EQA issuing body will be noted in this document until classed as resolved.

None of our laboratories has any issues of poor or persistent EQA performances within the last 12 months and have not been referred to any external Quality Advisory Panel.

## Approval

We hope that this declaration will assist you in your requirements for compliance with ISO15189. If should you require any additional information, please contact us at the following email address:

[HiNatnl@nhsbt.nhs.uk](mailto:HiNatnl@nhsbt.nhs.uk)

**Dr Katy Latham PhD FRCPATH**

**National Head of Histocompatibility and Immunogenetics**

**NHS Blood and Transplant**